Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Monday, November 11, 2019 · 501,853,950 Articles · 3+ Million Readers

Match Point Deepens Experience in Healthcare A.I., Data Analytics and Value-Based Collaboration Technologies with Deals in 2019

Match Point continues broad industry leadership in the healthcare technology sector with new deals in the growing fields of applied A.I., data analytics and value-based collaboration platforms

/EIN News/ -- NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Match Point Partners, a leading digital health advisory firm, advised Qcentive LLC on its Q3 2019 merger with Apervita, Inc., a leading cloud collaboration platform designed exclusively for the healthcare industry. Qcentive—a leader in value-based contract and alternative payment administration—was originally incubated and launched by Blue Cross Blue Shield of Massachusetts (BCBSMA) and its venture investment subsidiary, Zaffre Investments. The combined Apervita-Qcentive solution integrates clinical and financial insights and empowers payers and providers to create and manage value-based relationships that drive greater efficiency and quality of care. Previously, Match Point had advised Apervita on its 2017 financing round.

Commenting on the transaction and Match Point’s role, Patrick Gilligan, executive vice president of Sales, Marketing and Product for BCBSMA and chief executive of its venture investment subsidiary, Zaffre Investments, said, “We incubated Qcentive with the intent of sharing its innovations with the broader market. The combination of Apervita and Qcentive makes this vision a reality. Match Point hit a home run in making this match happen.”

Qcentive Co-founder and CEO Christopher Pilkington agreed, commenting, “Value-based relationships are critical building blocks to transforming the archaic way the U.S. buys and sells healthcare. The Apervita-Qcentive combination is the first healthcare industry platform with the ingredients to make that happen at scale. Kudos to Match Point for bringing us together.”

The Qcentive-Apervita deal followed the successful sale earlier this year of DoseMe® to Tabula Rasa HealthCare® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety. DoseMe’s unique AI-driven dosing solutions support physicians and pharmacists to accurately dose patient’s high-risk parenteral medications based on their individual needs, resulting in significant improvements to patient safety and outcomes.

“By uniting DoseMe and TRHC, we are able to more effectively support healthcare providers to enhance and accelerate medication safety solutions,” states Charles Cornish, CEO of DoseMe. “Together we believe we can power the shift to precision prescribing, tailoring medication to meet individual needs. This will have a profound impact on safety, quality and costs, including medication-related adverse drug events. Match Point was key in connecting our two innovative organizations.”

Brad Burkett, managing partner of Match Point commented, “Match Point’s unique hands-on style—leveraging its partners’ decades of CXO experience in early-stage companies and transactions—is extremely well suited to the fast-emerging fields of AI, analytics and platform-as-a-service. Early stage companies in these sectors have important solutions that will dramatically transform health care cost and quality. We are gratified to be able to assist talented ventures like Qcentive and DoseMe to grow and achieve their vision.”

Match Point was founded by entrepreneurs for entrepreneurs. Since its founding in 2009, we have assisted over 100 emerging healthcare firms to achieve outstanding success and exceed their vision.  

About Match Point Partners
Match Point Partners is a unique full service Digital Health advisory firm and investment bank comprised of experienced entrepreneurs, C-suite executives from sponsor-backed firms, and bankers with offices in New York City, San Francisco, and Washington D.C. For more information, please contact Brad Burkett at brad@mppartnersllc.com or visit www.mppartnersllc.com.

About DoseMe®
DoseMe is a Tabula Rasa HealthCare Company (NASDAQ: TRHC) and the first company in the world to develop precision dosing software - DoseMeRx - developed specifically for clinical practice. DoseMe's clinical decision support solutions focus on empowering healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs and improve patient outcomes. For more information, visit doseme-rx.com, or follow DoseMe on Twitter @DoseMeApp.

About Tabula Rasa HealthCare®
Tabula Rasa Healthcare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations.  For more information, visit tabularasahealthcare.com

Securities offered through Manor Park Securities LLC. Member FINRA / SIPC

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release